Cytosorbents Received The Recommendation From The Independent Data And Safety Monitoring Board, Following The Second Scheduled Safety Review, To Complete The Pivotal STAR-T Trial As Planned Without Any Modifications
Portfolio Pulse from Benzinga Newsdesk
Cytosorbents received a recommendation from the Independent Data and Safety Monitoring Board to complete the pivotal STAR-T trial without modifications. The trial evaluates the ability of DrugSorb-ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery.
June 15, 2023 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cytosorbents received a positive recommendation to complete the STAR-T trial without modifications, potentially leading to positive outcomes for the company's DrugSorb-ATR product.
The positive recommendation from the Independent Data and Safety Monitoring Board indicates that the trial is progressing well and is likely to yield positive results. This could lead to increased demand for DrugSorb-ATR and boost Cytosorbents' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100